GB Patent

GB2560019A — Use of cannabinoids in the treatment of leukaemia

Assigned to GW Research Ltd · Expires 2018-08-29 · 8y expired

What this patent protects

A combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) for use in the treatment of leukaemia is provided. The type of leukaemia is preferably one of acute lymphoblastic leukaemia (ALL), chronic lymphoblastic leukaemia (CLL), acute myeloid leukaemia (AML), chronic myelo…

USPTO Abstract

A combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) for use in the treatment of leukaemia is provided. The type of leukaemia is preferably one of acute lymphoblastic leukaemia (ALL), chronic lymphoblastic leukaemia (CLL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) or a childhood leukaemia. The combination of CBD and THC may be present in the form of a cannabis plant extract, a highly purified extract of cannabis which comprises at least 98% (w/w) of the particular cannabinoid or a synthetic compound. The combination of CBD and THC may further comprise a chemotherapeutic drug, preferably cytarabine or vincristine. The combination with vincristine is preferred with lymphoblastic leukaemia and the combination with cytarabine is preferred with myeloid leukaemia.

Drugs covered by this patent

Patent Metadata

Patent number
GB2560019A
Jurisdiction
GB
Classification
—
Expires
2018-08-29
Drug substance claim
No
Drug product claim
No
Assignee
GW Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.